Skip to main content

Table 1 Baseline characteristics and CGM parameters of the 26 patients

From: Relationship between glycemic intraday variations evaluated in continuous glucose monitoring and HbA1c variability in type 2 diabetes: pilot study

  Mean ± SD
Sex (male/female) 14/12
Age (year) 68.5 ± 7.8
Height (cm) 159.9 ± 8.2
Weight (kg) 62.5 ± 13.9
BMI (kg/m2) 24.3 ± 4.1
SBP (mmHg) 136.4 ± 16.8
DBP (mmHg) 73.7 ± 9.6
Duration of diabetes (years) 12.6 ± 10.0
Baseline HbA1c (%) 6.7 ± 0.6
Creatinine (mg/dL) 0.85 ± 0.23
eGFR (mL/min/1.73m2) 63.9 ± 14.2
Neuropathy [n (%)] 5 (19)
Retinopathy [n (%)] 2 (8)
Nephropathy [n (%)] 6 (23)
Diabetes treatment  
 Diet only [n (%)] 1 (4)
 SU [n (%)] 0
 Glinide [n (%)] 2 (8)
 DPP-4 inhibitor [n (%)] 17 (65)
 Biguanide [n (%)] 12 (46)
 Thiazolidine [n (%)] 5 (19)
 SGLT-2 inhibitor [n (%)] 7 (27)
 α-glucose inhibitor [n (%)] 5 (19)
 GLP-1 receptor [n (%)] 3 (12)
 Insulin [n (%)] 2 (8)
CGM parameters  
 Average glucose (mg/dL) 129.2 ± 21.1
 MODD (mg/dL) 27.5 ± 9.5
 SD (mg/dL) 33.1 ± 8.7
 CV (%) 25.6 ± 4.7
 Maximum (mg/dL) 214.0 ± 36.8
 Minimum (mg/dL) 81.3 ± 15.4
 TBR (%) 1.5 ± 2.5
 TIR (%) 87.1 ± 11.8
 TAR (%) 11.4 ± 11.8
 LBGI 1.6 ± 1.1
 HBGI 4.2 ± 2.3
  1. BMI: Body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; eGFR: estimated glomerular filtration rate; SU: sulfonylureas; DPP-4 inhibitor: dipeptidyl peptidase-4 inhibitor; SGLT-2 inhibitor: sodium-glucose transporter-2 inhibitor; GLP-1 receptor: Glucagon-like peptide-1 receptor; CGM: continuous glucose monitoring; MODD: mean of daily difference of blood glucose; SD: standard deviation; CV: coefficient of variation; TBR: time below range; TIR: time in range; TAR: time above range; LBGI: low blood glucose index; HBGI: high blood glucose index